| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Anthraquinones as a privileged scaffold in drug discovery targeting nucleotide-binding proteins
|
Baqi, Younis
|
|
2016
|
21 |
10 |
p. 1571-1577
7 p.
|
article
|
| 2 |
Chemistry and clinical relevance of carbohydrate degradation in drugs
|
Pischetsrieder, Monika
|
|
2016
|
21 |
10 |
p. 1620-1631
12 p.
|
article
|
| 3 |
Contents page 2
|
|
|
2016
|
21 |
10 |
p. ii-
1 p.
|
article
|
| 4 |
Contents page 1
|
|
|
2016
|
21 |
10 |
p. i-
1 p.
|
article
|
| 5 |
Corrigendum to “Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer” [Drug Discov. Today 20 (11) (2015) 1391–1397]
|
Blanden, Adam R.
|
|
2016
|
21 |
10 |
p. 1728-
1 p.
|
article
|
| 6 |
Current and emerging treatment options for spinal cord ischemia
|
Nardone, Raffaele
|
|
2016
|
21 |
10 |
p. 1632-1641
10 p.
|
article
|
| 7 |
Current progress in a second-generation claudin binder, anti-claudin antibody, for clinical applications
|
Hashimoto, Yosuke
|
|
2016
|
21 |
10 |
p. 1711-1718
8 p.
|
article
|
| 8 |
Customer pyramid framework for CAR T-cell therapies in immuno-oncology
|
Malik, Nafees N.
|
|
2016
|
21 |
10 |
p. 1563-1565
3 p.
|
article
|
| 9 |
Docking optimization, variance and promiscuity for large-scale drug-like chemical space using high performance computing architectures
|
Trager, Richard E.
|
|
2016
|
21 |
10 |
p. 1672-1680
9 p.
|
article
|
| 10 |
Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective
|
Ferreira, Leonardo G.
|
|
2016
|
21 |
10 |
p. 1699-1710
12 p.
|
article
|
| 11 |
Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target
|
Subbotin, Vladimir M.
|
|
2016
|
21 |
10 |
p. 1578-1595
18 p.
|
article
|
| 12 |
FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science
|
Fang, Hong
|
|
2016
|
21 |
10 |
p. 1566-1570
5 p.
|
article
|
| 13 |
Open for collaboration: an academic platform for drug discovery and development at SciLifeLab
|
Arvidsson, Per I.
|
|
2016
|
21 |
10 |
p. 1690-1698
9 p.
|
article
|
| 14 |
Pathophysiological implications of neurovascular P450 in brain disorders
|
Ghosh, Chaitali
|
|
2016
|
21 |
10 |
p. 1609-1619
11 p.
|
article
|
| 15 |
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
|
Bayliss, Martin K.
|
|
2016
|
21 |
10 |
p. 1719-1727
9 p.
|
article
|
| 16 |
Research and drug development activities in rare diseases: differences between Japan and Europe regarding influence of prevalence
|
Mizoguchi, Hirokuni
|
|
2016
|
21 |
10 |
p. 1681-1689
9 p.
|
article
|
| 17 |
Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca
|
Kettle, Jason G.
|
|
2016
|
21 |
10 |
p. 1596-1608
13 p.
|
article
|
| 18 |
Stapled peptide design: principles and roles of computation
|
Tan, Yaw Sing
|
|
2016
|
21 |
10 |
p. 1642-1653
12 p.
|
article
|
| 19 |
The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target
|
Simões, André E.S.
|
|
2016
|
21 |
10 |
p. 1654-1663
10 p.
|
article
|
| 20 |
Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes: a case study
|
Yang, Hsih-Te
|
|
2016
|
21 |
10 |
p. 1664-1671
8 p.
|
article
|
Journal description